Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
Swisse Ultiboost High Strength Deep Sea Krill Oil, Swisse Wellness Pty Ltd, CON-240
Product name
Swisse Ultiboost High Strength Deep Sea Krill Oil
Sponsor name
Swisse Wellness Pty Ltd
ARTG
292914
Consent start
Consent no.
CON-240
Standard
The United States Pharmacopeia-National Formulary (USP40-NF35) monograph for Krill Oil.
Non-compliance with standard
Non-compliance with The United States Pharmacopeia-National Formulary
(USP40-NF35) monograph for Krill Oil, the default standard for Krill Oil in
Australia. The raw material complies with the USP40-NF35 monograph, with the
exception of#58; 1. The concentrations of the fatty acids myristic acid
(C14#58;0), oleic acid (C18#58;1 n-9), and eicosapentoenoic acid (C20#58;5 n-3)
in the acceptance criteria for 'Identification Test A-Fatty Acid Profile' 2. The
ratio between palmitic acid (C16#58;0) and myristic acid (C14#58;0) in the
acceptance criteria for 'Identification Test A-Fatty Acid Profile' 3. The
acceptance criteria 'Content of Astaxanthin'
Conditions imposed
That the raw material meets the limits as set out in the table below#58;
Imposed limits for exempt Krill oil#58;
Test
Limits
1.
Identification Test A-Fatty Acid Profile
Myristic acid
5.0-13.0%
Oleic acid
6.0-14.5%
Eicosapentoenoic acid
14.0-28.0%
Ratio between palmitic and myristic acids
1.6-3.6%
2. Content of Astaxanthin
NLT 0.005%
NLT = Not less than
The raw material in relation to which the consent is given must comply with
all other applicable parts of the USP40-NF35 and all other applicable standards.
Therapeutic product type
Listed complementary medicines